Creatinine News and Research

RSS

Nerve growth factors sense OAB in children

Researchers may have found a reliable biomarker for diagnosing overactive bladder in children and monitoring their treatment outcome.

18 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

TGen's customized procedure produces high amounts of exosomes for treatment of CKD

Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.

12 Jul 2012

Measuring creatinine and cystatin C more accurately estimates kidney function

Measuring creatinine and cystatin C - two markers for chronic kidney disease (CKD) - more precisely estimates kidney function than either marker alone, according to a study funded by the National Institutes of Health. Results appear in the July 5 issue of the New England Journal of Medicine.

10 Jul 2012

Passive smoking risks children’s distance vision

Passive smoke exposure could lead to long-sightedness in children, show Egyptian study results.

29 Jun 2012

Risk score may aid emergency heart failure decisions

A novel risk score may help physicians decide whether to admit or discharge patients who present to the emergency department with an acute episode of heart failure, say its developers.

12 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.

11 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Bedside tool improves prognostication after cardiac arrest

A bedside prediction tool could estimate the probability of favorable neurologic survival in successfully resuscitated patients after in-hospital cardiac arrest, say researchers in the Archives of Internal Medicine.

30 May 2012

Intensive glucose control associated with reduced risk of albuminuria

A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication.

29 May 2012

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH).

28 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

A Better Method for Diagnosing Kidney Disease

Assessing glomerular filtration rate (GFR) using kidney filtration markers in blood is the standard means for determining kidney function, diagnosing kidney disease and measuring its progression. A higher filtration rate indicates healthy kidney function, while a lower rate points to various stages of kidney disease. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the new CKD-EPI equation for calculating GFR is a better predictor of risk for kidney disease and death compared to the most widely used method. The findings suggest that switching to the CKD-EPI equation for calculating GFR could focus efforts more efficiently, and improve assessment of patient future risk and treatment of kidney disease. The study is published in the May 9 edition of JAMA.

10 May 2012

CKD-EPI equation may provide more accurate risk prediction of death, ESRD

Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is the author of an invited editorial in JAMA. The editorial accompanied a study that included data from more than 1 million adults, and indicated the use of a newer risk prediction equation that classified fewer individuals as having chronic kidney disease and more accurately categorized the risk for death and end-stage renal disease.

9 May 2012

Two studies show true impact of liver disease across Europe

Two studies presented at the International Liver Congress- 2012 show the true impact that liver disease has across Europe. One highlights the financial cost of liver disease to the community and the second highlights the high mortality rates associated with cirrhosis.

19 Apr 2012

Fibrates to treat high cholesterol may affect kidney health

Older patients taking a common cholesterol medication should be cautious of the impact on their kidney health. In a new study by Dr. Amit Garg, Scientist at the Lawson Health Research Institute and the Institute for Clinical Evaluative Sciences (ICES), and colleagues, one in 10 new older fibrate users experienced a 50 per cent increase in their serum creatinine.

18 Apr 2012